Dr. Xinglei Shen
Claim this profileUniversity of Kansas Cancer Center
Area of expertise
Prostate Cancer
Xinglei Shen has run 9 trials for Prostate Cancer. Some of their research focus areas include:
Prostate Adenocarcinoma
Xinglei Shen has run 4 trials for Prostate Adenocarcinoma.
Affiliated Hospitals
University Of Kansas Cancer Center
University Of Kansas Cancer Center-Overland Park
Clinical Trials Xinglei Shen is currently running
Apalutamide + Hormone and Radiation Therapies
for Prostate Cancer
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting
2 awards
Phase 3
Lutetium (177Lu) Vipivotide Tetraxetan
for Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).
Recruiting
2 awards
Phase 3
6 criteria
More about Xinglei Shen
Clinical Trial Related
7 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Xinglei Shen has experience with
- Radiation Therapy
- Bicalutamide
- Relugolix
- Apalutamide
- Degarelix
- Histrelin
Breakdown of trials Xinglei Shen has run
Prostate Cancer
Prostate Adenocarcinoma
Financial Hardship
Bladder Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Xinglei Shen specialize in?
Xinglei Shen focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are Stage I.
Is Xinglei Shen currently recruiting for clinical trials?
Yes, Xinglei Shen is currently recruiting for 3 clinical trials in Kansas City Kansas. If you're interested in participating, you should apply.
Are there any treatments that Xinglei Shen has studied deeply?
Yes, Xinglei Shen has studied treatments such as Radiation Therapy, Bicalutamide, Relugolix.
What is the best way to schedule an appointment with Xinglei Shen?
Apply for one of the trials that Xinglei Shen is conducting.
What is the office address of Xinglei Shen?
The office of Xinglei Shen is located at: University of Kansas Cancer Center, Kansas City, Kansas 66160 United States. This is the address for their practice at the University of Kansas Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.